Latest news with #DaveRosa
Yahoo
7 days ago
- Business
- Yahoo
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025. Dave Rosa, President and CEO of NeuroOne will be meeting with investors during the two-day event that will feature informative panel discussions, keynote talks and corporate presentations on medical devices, imaging technologies, diagnostics, AI/data analytics and digital health. MedTech, AI & Digital Health ConferenceDates: June 3-4, 2025Location: O'Melveny Conference Center, San Francisco, CAConference registration: The MedInvest Conference is a leading conference series in Healthcare and Life Sciences. MedInvest hosts semiannual conferences in Biotech and Pharma and in MedTech, AI, and Digital Health. To learn more or to register, please visit their website: About NeuroOne NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit IR ContactMZ Group – MZ North AmericaNMTC@ in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
Baird says CEO ‘well-equipped' to further Intuitive Surgical position
After Intuitive Surgical (ISRG) announced this morning that President Dave Rosa will be promoted to Chief Executive Officer, Baird said the firm believes Rosa has long been slated to take over the CEO role, given his 29-plus years at the company. The firm, which expects Rosa to be 'well-equipped to continue to further ISRG's position as a best-in-class MedTech growth story,' keeps an Outperform and $575 price target on Intuitive Surgical shares. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ISRG: Disclaimer & DisclosureReport an Issue Intuitive Surgical Appoints David Rosa as CEO Intuitive Surgical announces promotion of Dave Rosa to CEO Wolfpack Research says short UFP Technologies, growth story 'in shambles' Intuitive Surgical Expands Stock Repurchase Program to $4B Intuitive Surgical announces FDA clearance of da Vinci Single Port system
